Business
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"Keros Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Keros Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/9bf10da51e4cb2ae9995ea0cc8482c22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_0RtSbQ0It0penXqmiH13w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9bf10da51e4cb2ae9995ea0cc8482c22","width":300,"height":106}},"lazy":false},{"type":"text","content":"Milestone payment of $10 million triggered under the global license agreement with Takeda","length":89,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes (“MDS”). The dosing of the first patient triggers a $10 million milestone payment to Keros under the global license agreement with Takeda.","length":717,"tagName":"p"},{"type":"text","content":"“The initiation of patient dosing in the RENEW trial marks an important next step in evaluating elritercept as a potentially differentiated therapy for patients with MDS,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer of Keros. “We are pleased to have achieved this milestone alongside our partner Takeda and look forward to seeing elritercept’s potential further explored for patients in need.”","length":413,"tagName":"p"},{"type":"text","content":"Under the terms of the global license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025, Keros received a $200 million upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1 billion. Keros will also be eligible to recei...